Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 118

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 118
---
 to promote and achieve the performance expectations
of executives of a specialty biopharmaceutical company. The NGCC is of the view that our executive compensation program should not encourage
senior executives to take inappropriate or unreasonable risk. In this regard, the NGCC recommends the implementation of compensation
methods that appropriately connect a portion of senior executive compensation with our short-term and longer-term performance, as well
as that of each individual executive officer and that take into account the advantages and risks associated with such compensation methods.
The NGCC is also responsible for establishing compensation policies that are intended to reward the creation of shareholder value while
reflecting a balance between our short-term and longer-term performance and that of each executive officer.

The NGCC is currently composed of Ms. Genevieve Foster
(Chair), Mr. William Li and Mr. Ulrich Kosciessa, each of whom is independent. The Board believes that the members of the NGCC collectively
have the knowledge, experience and background required to fulfill its mandate.

  81  

  Employees  
 ─────────────

As at December 31, 2024, we had a total of 40 active
employees, of which 29 are based in Canada, 10 are based in Frankfurt, Germany and 1 based in the U. S.

Our current employees are engaged in the following
activities: (i) 6 are engaged in research and development, regulatory affairs and quality assurance; (ii) 30 are involved in commercial
operations; and (iii) 14 are involved in various administrative functions, including corporate development, finance and accounting. We
do not employ any sales representatives.

We have agreements with our employees covering confidentiality,
loyalty, non-competition and assignment of all intellectual property rights developed during the employment period.

  Share ownership  
 ───────────────────

The table below sets forth information as of March
26, 2025 provided to us by our directors and named executive officers as of December 31, 2024 concerning their ownership of Common Shares
and stock options of the Company:

  Name                                                                 
  Miller, Ronnie           —            4,956       4,956      15,000  
  Ulrich, Kosciessa        1,848        5,428       5,428      12,500  
  Li, William              2,397        3,658       3,658      12,500  
  Labbe, Pierre            —                —           —